GET IN TOUCH
GelMEDIX Inc. is an early-stage biotechnology company committed to innovating the next generation of ocular and regenerative therapies through its proprietary hydrogel platform. GelMEDIX's programs are based upon its photo crosslinked hydrogels, originally developed by Prof. Nasim Annabi (UCLA) and Prof. Reza Dana (Mass Eye and Ear, Harvard Medical School). These hydrogels uniquely enable bioadhesion, tissue regeneration, tunable mechanics, and therapeutic loading across modalities from small molecules to cell and gene therapies. GelMEDIX is developing drug products for indications across the eye focused on cell-based therapies for vision restoration, intraocular sustained release of small molecules and peptides, and in situ forming bioadhesives. GelMEDIX is backed by Safar Partners and HTL Biotechnology along with leading angel investors and is currently raising a Series-A financing.
If you have general questions please email info@gelmedix.com. For finance related matters, please email finance@gelmedix.com. For hiring, please contact hr@gelmedix.com. For scientific and ordering questions, please email rd@gelmedix.com.
700 Main St North, c/o LabCentral, Cambridge, MA 02139
OPEN POSITIONS
Join Us
(SR.) SCIENTIST - STEM CELL BIOLOGY
Full Time
We are seeking an experienced, creative, and motivated (Sr.) Scientist to be a key member of our growing, cross-functional team working on the development and optimization of stem cell derived therapies and implantable formulations. While our focus is on ophthalmic indications, the position also allows for great breadth and opportunity in various disease areas, and the candidate may work on multiple programs in parallel at various stages of development. The candidate will report directly to the Chief Development Officer and will immediately work to build their own scientific team. This position is full-time with laboratory time being on-site at our facilities located in Cambridge, MA. Please inquiries or application materials to hr@gelmedix.com.
NEWS
HTL ANNOUNCES ITS INCUBATOR'S EQUITY INVESTMENT IN GELMEDIX, AN EARLY-STAGE BIOTECH AIMING AT REVOLUTIONIZING OCULAR AND REGENERATIVE THERAPIES
March 10, 2022